Literature DB >> 31813288

Preparation and evaluation of PEGylated Asiatic Acid Nanostructured Lipid Carriers on anti-fibrosis effects.

Xiaoxiao Chen1,2, Yawen Zhang2, Pengfei Zhao3,4, Yan Chen1,2, Yunli Zhou1,2, Shenghao Wang1,2, Lina Yin2.   

Abstract

Liver fibrosis is a major pathological feature of chronic liver diseases, and effective therapies are limited at present. Asiatic acid (AA) is a triterpenoid isolated from Centella Asiatica, which exhibits efficient anti-inflammatory and anti-oxidative activities. However, AA shows very low plasma levels after oral administration. In this study, AA loading PEGylated nanostructured lipid carriers (P-AA-NLC) were prepared. P-AA-NLC were characterized for particle size distribution, polydispersity index, entrapment efficiency, X-ray powder diffraction pattern (XRD), differential scanning colorimeter (DSC) and transmission electron microscopy (TEM). The intestinal absorption, in vivo distribution, pharmacokinetics and anti-fibrosis effects of P-AA-NLC were studied compared with that of AA-NLC. In situ single-pass intestinal perfusion model shown that there are significant differences in absorption between the free and NLCs formulation. The Peff values of P-AA-NLC were significantly enhanced in all four intestinal segments compared to AA-NLC and free AA (P < 0.05). fa% and Ka showed similar trends, suggesting the PEGylated NLC can improve the gastrointestinal absorption of the drug. The pharmacokinetic studies presented that P-AA-NLC prolonged blood circulation times with a 1.5-fold higher relative bioavailability compared with AA-NLC. In vivo distribution experiments demonstrated that the fluorescence concentration in the liver was higher than that in other organs and the fluorescence intensity in the liver of DIR-P-NLC was about 1.3 times that of DIR-NLC. In addition, oral administration of P-AA-NLC can significantly attenuate CCl4-induced liver fibrosis and functional impairment in a dosage-dependent manner, including an increase in the ALB and decrease in AST and ALT. Moreover, the MDA and HYP in liver tissue were downregulated, while the SOD activity was upregulated. In conclusion, P-AA-NLC can increase gastrointestinal absorption of AA and enhance anti-liver fibrosis effects in SD rats.

Entities:  

Keywords:  Anti-liver fibrosis; Asiatic acid; Liver targeting strategy; PEGylated nanostructured lipid carriers; Pharmacokinetics

Year:  2019        PMID: 31813288     DOI: 10.1080/03639045.2019.1701002

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  4 in total

1.  Liver-targeted delivery of asiatic acid nanostructured lipid carrier for the treatment of liver fibrosis.

Authors:  Ya-Wen Zhang; Ling-Lan Tu; Yi Zhang; Jie-Chao Pan; Gao-Li Zheng; Li-Na Yin
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

2.  In Vivo Biocompatible Self-Assembled Nanogel Based on Hyaluronic Acid for Aqueous Solubility and Stability Enhancement of Asiatic Acid.

Authors:  Yu Yu Win; Penpimon Charoenkanburkang; Vudhiporn Limprasutr; Ratchanee Rodsiri; Yue Pan; Visarut Buranasudja; Jittima Amie Luckanagul
Journal:  Polymers (Basel)       Date:  2021-11-23       Impact factor: 4.329

3.  Enhanced circulation longevity and pharmacodynamics of metformin from surface-modified nanostructured lipid carriers based on solidified reverse micellar solutions.

Authors:  Franklin Chimaobi Kenechukwu; God'spower Tochukwu Isaac; Daniel Okwudili Nnamani; Mumuni Audu Momoh; Anthony Amaechi Attama
Journal:  Heliyon       Date:  2022-03-15

Review 4.  Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders.

Authors:  Alexandros Marios Sofias; Federica De Lorenzi; Quim Peña; Armin Azadkhah Shalmani; Mihael Vucur; Jiong-Wei Wang; Fabian Kiessling; Yang Shi; Lorena Consolino; Gert Storm; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2021-06-15       Impact factor: 15.470

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.